Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ZFP37 CRISPR/Cas9 KO Plasmid (h): sc-416996
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ZFP37 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ZFP37 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ZFP37 Antibody (15): sc-293086
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ZFP37 CRISPR/Cas9 KO Plasmid (h) | sc-416996 | 20 µg | $397.00 |
Overview
ZFP37 (zinc finger protein 37) is a human KRAB-domain C2H2 zinc-finger transcription factor implicated in sequence-specific DNA binding and transcriptional repression. As part of KRAB–KAP1/TRIM28-associated chromatin regulatory complexes, ZFP37 is expected to influence heterochromatin formation, epigenetic silencing, and maintenance of cell-type-specific transcriptional programs. These activities connect ZFP37 to core nuclear processes such as chromatin organization, genome stability, and control of repetitive element expression. Altered regulation of KRAB zinc-finger pathways has been associated with dysregulated differentiation and oncogenic transcriptional states, motivating investigation of ZFP37 in disease-relevant gene regulatory networks.
ZFP37 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ZFP37 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ZFP37 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ZFP37 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ZFP37 protein expression.
This CRISPR knockout system enables efficient generation of ZFP37-deficient cell models for investigation of ZFP37 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ZFP37 exon(s) critical for ZFP37 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ZFP37 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ZFP37 CRISPR/Cas9 KO Plasmid (h) and ZFP37 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ZFP37 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ZFP37 HDR Plasmid (h) and ZFP37 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ZFP37 homology arms to support homology-directed repair at defined ZFP37 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.